Business Context and Reporting Period
Company: Viridian Therapeutics, Inc. (VRDN)
Filing Type: Form 8-K (Current Report)
Date of Report: May 24, 2026
Event: Entry into a Material Definitive Agreement for commercial manufacturing services.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the terms of a new commercial agreement.
Material Changes and Agreement Details
On May 24, 2026, the Company entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited to manufacture and supply the anticipated long-term commercial requirements for its drug candidate, veligrotug (drug substance and drug product).
- Scope: Manufacturing and supply of veligrotug for commercial use, contingent on regulatory approval.
- Supplier Status: WuXi Biologics is a non-exclusive supplier; the Company retains the right to procure from alternate manufacturers.
- Pricing Structure: Volume-based pricing. Service fees are fixed until December 31, 2026, after which they may be annually adjusted based on volume. The Company will reimburse certain pass-through costs.
- Forecasting: The Company must provide rolling monthly volume forecasts, a portion of which constitutes a binding, non-cancellable commitment.
- Term: Initial term of five years with automatic renewal for successive five-year periods unless non-renewal notice is given 24 months prior to expiration.
- Termination: The Company may terminate with 30 days' notice if applicable laws materially and adversely impact WuXi Biologics' ability to perform. Either party may terminate for uncured material breach or insolvency.
Guidance, Outlook, and Risks
Outlook: The agreement supports the Company's preparation for the potential commercial launch of veligrotug, securing long-term supply capabilities.
Risks: The agreement is contingent upon regulatory approval of the Product. The Company faces potential costs associated with binding volume commitments if commercial demand does not meet forecasts. The full text of the agreement is not included in this filing and will be filed as an exhibit to the Form 10-Q for the period ended June 30, 2026.
Investor Verification Checklist
- Verify the regulatory approval status of veligrotug, as the manufacturing agreement is contingent on approval.
- Review the upcoming Form 10-Q (due after June 30, 2026) for the full text of the agreement and specific volume commitment thresholds.
- Assess the Company's cash runway and ability to fund the binding volume commitments and pass-through costs under the new agreement.
- Monitor for any announcements regarding alternate manufacturers, given the non-exclusive nature of the supplier relationship.